{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:53:51Z","timestamp":1770756831674,"version":"3.50.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xkme.2025.101223","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:19:17Z","timestamp":1765901957000},"page":"101223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caveolin-1 as a Marker of Endothelial Damage in Primary Antiphospholipid Syndrome Nephropathy"],"prefix":"10.1016","volume":"8","author":[{"given":"Savino","family":"Sciascia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Barinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2025.101223_bib1","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.xkme.2025.101223_bib2","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xkme.2025.101223_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semnephrol.2015.08.009","article-title":"Antiphospholipid syndrome and the kidney","volume":"35","author":"Sciascia","year":"2015","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2025.101223_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.xkme.2025.101223_bib5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000529229","article-title":"Antiphospholipid syndrome and kidney involvement","volume":"48","author":"De Simone","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.xkme.2025.101223_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ekir.2023.01.018","article-title":"Clinical- pathological characteristics of renal injuries identify different clusters in patients with antiphospholipid antibodies","volume":"8","author":"Sciascia","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.xkme.2025.101223_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/1874467214666211130155902","article-title":"Caveolin-1: a promising therapeutic target for diverse diseases","volume":"15","author":"Gokani","year":"2022","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.xkme.2025.101223_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00432-016-2285-2","article-title":"Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma","volume":"143","author":"Shimizu","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101223_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11892-017-0844-9","article-title":"Caveolin-1 in the pathogenesis of diabetic nephropathy: potential therapeutic target?","volume":"17","author":"Van Krieken","year":"2017","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.xkme.2025.101223_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2020.11.020","article-title":"Caveolin-1 in autophagy: A potential therapeutic target in atherosclerosis","volume":"513","author":"Hou","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.xkme.2025.101223_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578309","article-title":"Caveolin-1 mediates blood-brain barrier permeability, neuroinflammation, and cognitive impairment in SARS-CoV-2 infection","volume":"388","author":"Trevino","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101223_bib12","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0341","article-title":"Interplay between caveolin-1 and mineralocorticoid receptor in cardiometabolic disease","volume":"262","author":"Czarzasta","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.xkme.2025.101223_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.matbio.2013.03.005","article-title":"Role of caveolin-1 in fibrotic diseases","volume":"32","author":"Gvaramia","year":"2013","journal-title":"Matrix Biol"},{"key":"10.1016\/j.xkme.2025.101223_bib14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3892\/or.2011.1605","article-title":"Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas","volume":"27","author":"Zhan","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.xkme.2025.101223_bib15","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s40620-023-01645-5","article-title":"Caveolin-1 in situ expression in glomerular and peritubular capillaries as a marker of ultrastructural progression and severity of renal thrombotic microangiopathy","volume":"36","author":"Vasuri","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.xkme.2025.101223_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ctr.12833","article-title":"The prognostic values of caveolin-1 immunoreactivity in peritubular capillaries in patients with kidney transplantation","volume":"30","author":"Nakada","year":"2016","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2025.101223_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13023-021-01906-1","article-title":"Reducing the diagnostic delay in antiphospholipid syndrome over time: a real world observation","volume":"16","author":"Radin","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.xkme.2025.101223_bib18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/biomedicines9101318","article-title":"Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel","volume":"9","author":"Gambella","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.xkme.2025.101223_bib19","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xkme.2025.101223_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/09612033231217351","article-title":"The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy","volume":"33","author":"Aluf","year":"2024","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.xkme.2025.101223_bib21","article-title":"Complement- mediated thrombotic microangiopathy in a patient with antiphospholipid syndrome and anti-glomerular basement membrane antibodies","volume":"15","author":"Gallant","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.xkme.2025.101223_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.ackd.2019.08.012","article-title":"Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus","volume":"26","author":"Kotzen","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.xkme.2025.101223_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.xkme.2025.101223_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \"antiphospholipid antibody nephropathy\" for the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.xkme.2025.101223_bib25","first-page":"7369","article-title":"Thrombotic microangiopathy in primary antiphospholipid syndrome is linked to stroke and less deep venous thrombosis","volume":"25","author":"Freire De Carvalho","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.xkme.2025.101223_bib26","first-page":"597","article-title":"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: study protocol","volume":"41","author":"Sciascia","year":"2023","journal-title":"Clin Exp Rheumatol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:32:44Z","timestamp":1770366764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525002596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2590059525002596"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101223","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caveolin-1 as a Marker of Endothelial Damage in Primary Antiphospholipid Syndrome Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101223"}}